StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) stock

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)

Close on Nov 17, 2026Market cap $152.14MP/E –Yield –

Korsana Biosciences price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Korsana Biosciences's price to sales ratio was 71.3× on Nov 11, 2026, against 14.3× a year earlier. Over the last 5 years it ranged from 5.7× to 445.0×, with a median of 113.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202671.3×+59.8
2025Dec 31, 202511.5×−282.5
2024Dec 31, 2024294.1×+134.9
2023Jul 31, 2023159.1×+30.2
2022Dec 30, 2022128.9×−18.3
2021Dec 31, 2021147.2×−52.4
2020Dec 31, 2020199.6×–

More Korsana Biosciences figures

See a number that looks wrong?